TABLE 1

Disease progression, as measured by percentage of predicted forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) at 6, 12, 24 and 36 months after initiation of nintedanib in the studied population

Start of treatment6 months12 months24 months36 months
Patients24421820211159
Deaths since last time point21172416
Patients with PFT values242 (99.2)150 (68.8)128 (63.4)60 (54.0)27 (45.8)
FVC% pred73.3±20.773.9±21.374.6±23.475.6±21.778.0±20.1
p=0.481p=0.136p=0.028p=0.074
DLCO% pred42.6±16.742.6±16.044.1±16.542.1±14.640.4±18.1
p=0.016p=0.892p=0.002p=0.334

Data are presented as n, n (%) or mean±sd, unless otherwise stated. Patients were censored from the pulmonary function test (PFT) analysis after death and/or discontinuation. Bold p-values are statistically significant.